Bleeding avoidance strategies for percutaneous coronary interventions continue to evolve with the availability of newer antiplatelet and anticoagulation therapies. Advances in interventional practices have altered the balance between ischemic and bleeding complications. With the availability of rapidly-acting platelet adenosine diphosphate-receptor antagonists, the need for routine glycoprotein IIb/IIIa inhibitors has diminished. Recent meta-analyses and trials have Reduction in bleeding events is associated with improved survival, and prevention of major bleeding may represent an important step in improving outcomes by balancing the safety and efficacy of pharmacotherapy and devices used during PCI (9).
B
leeding and vascular complications in patients undergoing percutaneous coronary interventions (PCIs) are associated with significant costs, prolonged hospital stays, and increased short-and long-term morbidity and mortality (1) (2) (3) (4) (5) . The risk of bleeding is modifiable, and improving bleeding and vascular complication rates provides an opportunity to improve the health care and safety of PCI. In that regard, the Centers for Medicare and Medicaid Services (6) have identified bleeding and hematoma following cardiovascular procedures as quality indicators (7).
Marso et al. (8) used the term "bleeding avoidance strategies" to highlight the importance of bivalirudin and vascular closure devices (VCDs) in reducing bleeding, using data on more than 1.5 million patients undergoing PCI at hospitals participating in the National Cardiovascular Data Registry (NCDR) (8) . In high-risk patients, the use of both bivalirudin and VCD was associated with significantly lower bleeding rates. Since the publication of this study, pharmacotherapy and technological advances have shed new light on factors that can further mitigate bleeding risk in patients undergoing PCI.
With this backdrop, this review will report recent advances associated with meaningful reduction in bleeding complications following PCI. It will also review the current data on the status of bivalirudin and VCD. Last, this review will provide the reader with a practical strategy to help individualize a patient's bleeding risk and deploy interventions to reduce bleeding in high-risk patients.
DEFINITION OF BLEEDING
Bleeding complications have been identified as a crucial endpoint to test the safety and efficacy of new antithrombotic drugs, cardiac devices, or PCI.
Reduction in bleeding events is associated with improved survival, and prevention of major bleeding may represent an important step in improving outcomes by balancing the safety and efficacy of pharmacotherapy and devices used during PCI (9) .
Lack of unanimity in defining bleeding has led to variation in the incidence of bleeding across institutions performing PCI (1) Figure 3) (27). The second model is derived from the NCDR database, is contemporary, and can be used even in patients undergoing elective PCI ( Figure 4 ) (11).
A patient with a higher bleeding risk can be easily identified with these models (e.g., elderly women presenting with ACS), allowing bleeding avoidance strategies to be preferentially targeted to these patients (28).
PROGNOSTIC IMPLICATIONS OF BLEEDING
Bleeding following PCI is associated with an increased risk of adverse cardiovascular outcomes (17,29-33). Higher risks for mortality, MI, and stent 
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This contemporary model is derived from the National Cardiovascular Data Registry (NCDR), is integer-based, and is parsimonious. BIVALIRUDIN AND PCI. Bivalirudin is an intravenous direct thrombin inhibitor that is used as an (69, 70, 72) . With heterogeneity in trial inclusion criteria and with the majority of deaths in patients without a major bleed, there is a lack of a distinct, mechanistic link between mortality reduction and radial access that was observed in some studies (34) .
However, these results underscore the need to use radial access in this subgroup, which is the most prone to bleeding complications following PCI.
In addition to lowering bleeding complications, radial access has cost advantages, promotes early ambulation and discharge, and is preferred by patients (1, 70, 73) . However, despite these advantages, there is a distinct learning curve for proficiency in using radial artery access for cardiac catheterization and PCI. In a pre-specified subgroup analyses from the RIVAL trial, the primary outcome was reduced These are the same variables that increase the risk of bleeding, and their cautious use or avoidance would be recommended until additional data are accrued.
ADOPTION OF BEST PRACTICES TO LOWER BLEEDING COMPLICATIONS
Recent analyses of a nationally-representative U.S.
PCI population suggest that 12.1% of all in-hospital mortality after PCI may be related to bleeding complications, and may therefore be modifiable, and that the number needed to harm (NNH) calculations suggest that the mortality risk associated with bleeding was greatest in patients at the highest bleeding risk (NNH ¼ 21) or with nonaccess-site bleeding (NNH ¼ 16) (5) . Likewise, the NNH was lowest in patients age 75 years or older and in patients with STEMI or low glomerular filtration rate. These high-risk subgroups may have the greatest potential for mortality reduction through bleeding avoidance and should be preferentially targeted.
Individualizing and stratifying bleeding risk before coronary angiography and intervention is paramount (Central Illustration). Not only can one tailor the choice of vascular access, but modification of anticoagulation strategies by pre-treatment with dual antiplatelet therapy and use of bivalirudin to lower access-and nonaccess-site bleeds in patients deemed to be higher risk will likely lower their bleeding complications. Excessive bleeding is also associated with acute kidney injury and ischemic complications; thus, preventing bleeding complications will translate into overall improvement in PCI outcomes (98) .
Recognition and mitigation of bleeding risk following PCI is a recognized health care priority.
Despite consistent observations from contemporary registry data documenting reductions in vascular and bleeding complications, there is still a paucity of systematic efforts to lower bleeding in these patients. 
